Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited develops epigenetics-based diagnostics through its Nucleosomics platform, which measures nucleosomes in blood and other bodily fluids. The company’s Nu.Q® product portfolio spans human diagnostics and monitoring for cancer, sepsis, trauma biomarker research and other disease areas, as well as veterinary oncology through Nu.Q® Vet assays.
VNRX news covers clinical publications and assay-development milestones, commercialization of Nu.Q® tests, veterinary cancer-test development, recombinant nucleosome products under rNuQ™, licensing and distribution activity, financial results, non-dilutive funding, equity financing and NYSE American listing-compliance matters. Volition’s research and development activities are centered in Belgium, with additional operations in the United States and London.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced the completion of its underwritten public offering of 4,945,000 shares at $1.75 per share, yielding approximately $8.7 million in gross proceeds. The offering included full exercise of the underwriter's overallotment option. Net proceeds will be allocated for research, product development, clinical studies, commercialization, working capital, and potential strategic acquisitions. The shares were issued under a previously filed shelf registration statement with the SEC. Newbridge Securities Corporation acted as the sole book-running manager for this offering.
VolitionRx Limited (NYSE AMERICAN: VNRX) has announced a public offering of 4,300,000 shares at $1.75 each, expected to generate approximately $7.525 million in gross proceeds. The closing of the offering is anticipated on February 22, 2023, pending customary conditions. The company plans to utilize the net proceeds for various purposes, including research, product development, clinical studies, and potential strategic acquisitions. Additionally, an underwriter has a 30-day option to purchase up to 645,000 additional shares to cover over-allotments. This offering follows a shelf registration statement with the SEC filed in September 2021.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced an underwritten public offering of its common stock on February 16, 2023. The offering includes a 30-day option for the underwriter to purchase up to an additional 15% of the offered shares. Proceeds from the offering are earmarked for research, product development, clinical studies, product commercialization, working capital, and potential strategic acquisitions. The final terms of the offering will be subject to market conditions and cannot be guaranteed. Newbridge Securities Corporation is the sole book-running manager for this offering.
VolitionRx Limited (NYSE American: VNRX) has announced the pre-order availability of its Nu.Q® Vet Cancer Test for veterinarians through Heska Corporation (NASDAQ: HSKA). This innovative test will be showcased at the 2023 Western Veterinary Conference in Las Vegas. The Nu.Q® test operates on Heska's Element i+® Immunodiagnostic Analyzer, providing rapid and accurate on-site testing for under $50, assisting in early cancer detection in dogs. The collaboration signifies a breakthrough in making Volition's Nucleosomics™ technology accessible at the point of care, enhancing veterinary care and patient outcomes. The commercial launch is targeted for early Q2 2023.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced participation in a webinar on January 26, 2023, focusing on the Nu.Q® Vet commercial strategy. Key speakers include CEO Dr. Tom Butera and Chief Medical Officer Dr. Heather Wilson Robles. The event aims to provide insights into the Nu.Q® Vet Cancer Test, a cost-effective blood test for early detection in dogs. Volition is exploring significant market opportunities in companion animal healthcare. The webinar will be recorded for later access. Volition develops blood tests for diagnosing diseases, leveraging its Nucleosomics™ platform.
VolitionRx Limited (NYSE AMERICAN: VNRX) has announced the launch of its Nu.Q® Vet Cancer Test through the IDEXX Laboratories reference laboratory network in the U.S. This innovative blood test is designed to detect cancer in older or at-risk dogs, leveraging Volition's Nucleosomics™ technology. IDEXX aims to use this test to enhance pet health and wellbeing by facilitating earlier diagnosis and treatment. With a significant potential market, this partnership is expected to expand Volition’s reach in the companion animal healthcare sector.
VolitionRx Limited (NYSE AMERICAN: VNRX) released its 2022 Business Review, highlighting significant progress as it transitions from an R&D-focused entity to one with commercial operations. Key achievements include global expansion of the Nu.Q® Vet Cancer Test, obtaining a CE mark for Nu.Q® NETs, initiating U.S. clinical product programs, and scaling operations. President Cameron Reynolds emphasized the company's advancements in epigenetics and its commitment to improving health outcomes.
VolitionRx Limited (NYSE AMERICAN: VNRX) reported its third-quarter financial results for the period ending September 30, 2022. The company held a conference call on November 15, 2022, to discuss these results. Volition's cash and cash equivalents totaled approximately $16.4 million. The company received $6.4 million from a public offering and $1.5 million from non-dilutive funding. The Nu.Q® Vet Cancer Test launched in the U.S. and will soon be available in Europe. Volition aims to license its Nu.Q® platform and continues advancing several key clinical studies.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced a clinical study in collaboration with Oncovet to evaluate its Nu.Q® Vet Cancer Test in dogs and cats with cancer. Led by Dr. Jérôme Benoit, the study aims to assess the detection of various systemic cancers by measuring circulating nucleosomes. The research will involve samples from 100 dogs and 25 cats and is expected to enhance the test's applications in Europe. Previous studies indicated the Nu.Q® Vet Cancer Test detected 76% of systemic cancers with 97% specificity.
VolitionRx Limited (NYSE AMERICAN: VNRX) has been invited to join a government-backed study in France to assess blood biomarkers for early lung cancer detection, partnering with Hospices Civils de Lyon. The ILYAD study aims to evaluate Volition's Nu.Q® test in detecting lung cancer, involving over 400 subjects over the next year. Chief Commercial Officer Gael Forterre emphasized the critical need for effective lung cancer screening globally. Volition specializes in developing cost-effective blood tests using its innovative Nucleosomics™ technology.